IER3 and ovarian carcinoma: The growing body of evidence suggests that IER3 is correlated to the prognosis of various cancers (Wu et al., 2013), including bladder cancer (Ye et al., 2018), ovarian cancer (Han et al., 2011), and pancreatic cancer (Sasada et al., 2008).